Ira Berkower

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120
    Ira Berkower
    Laboratory of Immunoregulation, Division of Viral Products, Office of Vaccine Research and Review, Center for Biologics, Bethesda, MD 20892, USA
    Virology 321:75-86. 2004
  2. ncbi Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding
    Ira Berkower
    Laboratory of Immunoregulation, DVP, Office of Vaccine Research and Review, Center for Biologics, FDA, Bldg 29, Room 523, NIH Campus, Bethesda, MD 20892, USA
    Virology 377:330-8. 2008
  3. ncbi Hepatitis B virus surface antigen assembly function persists when entire transmembrane domains 1 and 3 are replaced by a heterologous transmembrane sequence
    Ira Berkower
    Center for Biologics, FDA, Bethesda, MD 20892, USA
    J Virol 85:2439-48. 2011
  4. ncbi Stable expression of a foreign protein by a replication-competent rubella viral vector
    Angelo Spadaccini
    Lab of Immunoregulation, DVP, Office of Vaccine Research and Review, Center for Biologics, FDA, USA
    Vaccine 28:1181-7. 2010
  5. ncbi Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity
    Yong He
    Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD, USA
    J Infect Dis 196:1026-32. 2007
  6. ncbi Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions
    Konstantin Virnik
    Lab of Immunoregulation, Division of Viral Products, Office of Vaccines, Center for Biologics, FDA, Bldg 29, Room 523, NIH Campus, Bethesda, MD 20892, United States
    Vaccine 31:2119-25. 2013
  7. ncbi Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers
    Konstantin Virnik
    Lab of Immunoregulation, Division of Viral Products, Office of Vaccines, Center for Biologics, FDA, NIH Campus, Bethesda, MD 20892, USA
    Vaccine 30:5453-8. 2012

Collaborators

Detail Information

Publications7

  1. ncbi Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120
    Ira Berkower
    Laboratory of Immunoregulation, Division of Viral Products, Office of Vaccine Research and Review, Center for Biologics, Bethesda, MD 20892, USA
    Virology 321:75-86. 2004
    ..These gp120-rich particles can enhance the quality, as well as quantity, of antibodies elicited by a gp120 vaccine...
  2. ncbi Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding
    Ira Berkower
    Laboratory of Immunoregulation, DVP, Office of Vaccine Research and Review, Center for Biologics, FDA, Bldg 29, Room 523, NIH Campus, Bethesda, MD 20892, USA
    Virology 377:330-8. 2008
    ..Modified forms of gp120, in which the CD4 binding site is more exposed and accessible to antibodies, could provide novel immunogens for eliciting antibodies to this broadly shared neutralizing determinant...
  3. ncbi Hepatitis B virus surface antigen assembly function persists when entire transmembrane domains 1 and 3 are replaced by a heterologous transmembrane sequence
    Ira Berkower
    Center for Biologics, FDA, Bethesda, MD 20892, USA
    J Virol 85:2439-48. 2011
    ..The membrane-proximal exposed region (MPER) of gp41 is an important target of broadly reactive neutralizing antibodies against HIV-1, and HBsAg-MPER particles may provide a good platform for future vaccine development...
  4. ncbi Stable expression of a foreign protein by a replication-competent rubella viral vector
    Angelo Spadaccini
    Lab of Immunoregulation, DVP, Office of Vaccine Research and Review, Center for Biologics, FDA, USA
    Vaccine 28:1181-7. 2010
    ..Further progress in expressing exogenous viral antigens in rubella may produce live viral vectors capable of immunizing against viruses for which attenuation is not currently feasible...
  5. ncbi Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity
    Yong He
    Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD, USA
    J Infect Dis 196:1026-32. 2007
    ..These findings demonstrate that A27 antibodies do not represent the major fraction of neutralizing activity in VIG and suggest that immunity may be augmented by vaccines and immune globulins that include strong antibody responses to A27...
  6. ncbi Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions
    Konstantin Virnik
    Lab of Immunoregulation, Division of Viral Products, Office of Vaccines, Center for Biologics, FDA, Bldg 29, Room 523, NIH Campus, Bethesda, MD 20892, United States
    Vaccine 31:2119-25. 2013
    ..The rubella vaccine strain readily infects rhesus macaques, and these animals will be the model of choice for testing vector growth in vivo and immunogenicity...
  7. ncbi Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers
    Konstantin Virnik
    Lab of Immunoregulation, Division of Viral Products, Office of Vaccines, Center for Biologics, FDA, NIH Campus, Bethesda, MD 20892, USA
    Vaccine 30:5453-8. 2012
    ..Rubella readily infects rhesus macaques, and these animals will provide an ideal model for testing the new vectors for replication in vivo, immunogenicity, and protection against SIV or SHIV challenge...